After one month, increased procollagen production was seen in 7 out of 10 participants using copper tripeptide (more than those using vitamin C, melatonin, or tretinoin
Product Specifications Compound: Epithalon (Epitalon) Class: Synthetic short-chain tetrapeptide Sequence: Ala-Glu-Asp-Gly Molecular Weight: ~390 Da Form: Lyophilized powder Vial Size: 35 or 50mg in 5ml glass vial Purity: 99%+ verified by HPLC and mass spectrometry (See COAs) Research Background Epithalon has been investigated in research literature across several scientific contexts: Telomere biology research investigations into cellular telomerase activity and telomere maintenance in cell culture research models Pineal gland cellular biology studies examining cellular signaling pathways in pineal cellular research contexts Cellular gene expression research research literature on short-chain peptide effects on gene expression patterns in cellular research models Cellular regulatory peptide research analytical studies on tetrapeptide structure-activity relationships and cellular regulatory mechanisms Comparative short-chain peptide research comparative cellular research positioning Epithalon alongside other Khavinson-group short-chain regulatory peptides (including Cartalax) in cellular research contexts Cellular aging research studies examining cellular regulatory peptide effects across cellular aging research models Epithalon was developed through cellular biology research by the Khavinson research group at the St
Input factors whose corresponding PRCC value is negative are designated with a negative sign in parentheses
These medications mimic the actions of the endogenous incretin hormone GLP-1 by enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety.[1] Incretin hormones also exert effects across multiple organ systems, including cardiovascular, renal, and skeletal systems.[1] Owing to these pleiotropic mechanisms, the clinical use of GLP-1RAs has expanded exponentially, both for diabetes and for a broadening spectrum of diseases and conditions.[2] Obesity plays a central role in the pathogenesis and progression of T2DM, yet many traditional glucose-lowering therapies are associated with weight gain.[3] The observation that GLP-1RAs not only improve glycemic control but also result in significant weight loss marked a paradigm shift in diabetes pharmacotherapy, prompting investigation into their therapeutic potential in individuals without diabetes to treat obesity and related comorbidities.[4] Subsequently, large-scale cardiovascular and kidney outcome trials have demonstrated additional benefits of GLP-1RAs, further supporting their use in high-risk populations independent of diabetes status.[4] These trials resulted in a rapid evolution of the clinical landscape for GLP-1RAs in the last decade, with growing evidence supporting their role in treating obesity, cardiovascular disease, chronic kidney disease (CKD), and other metabolic-related disorders.[520] This expansion reflects both their favorable efficacy profile and their broader physiological effects
Although I am currently two thumbs down about microdosing compounded and fake GLP-1s for cosmetic weight loss or any medical condition, I am very excited about the weight-independent effects of GLP-1 treatment
,aspect=ignore)
